Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD subjects otherwise endure for many years of treatment.
Ticker:
LUMO
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Metabolic Diseases
Lead Product in Development:
LUM-201
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
